[Correspondence] Antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against SARS-CoV-2 omicron subvariants including JN.1, KP.3.1.1, and XEC
As of November, 2024, SARS-CoV-2 omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2),1 KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC2—a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3)—have been circulating in seve...